Compare Ascendis Pharma A/S (ASND) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs ProShares Ultra Semiconductors — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while ProShares Ultra Semiconductors trades at $92.9. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, ProShares Ultra Semiconductors nearer its low. Which is the better fit depends on your goals.
| ASND | USD | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $277.18 | $113.53 |
52-Week Low | $163.32 | $38.89 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
USD stock trades at $96.96, up 3.09% today, but technical indicators show a bearish bias with mixed signals. The stock faces resistance near $99 and support at $92. Recent news highlights include earnings reports from various companies, though specific financials for USD are not detailed in the provided data. The overall market sentiment is cautious, with oscillators neutral and moving averages slightly bullish.
The outlook for USD is clouded by bearish technicals and limited fundamental data. Investment opportunities may arise if the stock breaks above resistance, but risks include market volatility and lack of recent earnings visibility. Investors should await clearer financial updates to assess valuation and growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
